Evidence map›Paper›PMID 26884875›Full record

ArticleInternational journal of clinical and experimental pathology2015

Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.

Omar I Saadah, Sameer E Al-Harthi, Jamil A Al-Mughales, Yagoub Y Bin-Taleb, Raed S Baeshen

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Associations ofHeliyon · 2024
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Omar I SaadahDivision of Pediatric Gastroenterology / Department of Pediatrics, Faculty of Medicine, King Abdulaziz UniversityJeddah, Saudi Arabia; Inflammatory Bowel Disease Research Group, King Abdulaziz UniversityJeddah, Saudi Arabia.
Sameer E Al-HarthiDepartment of Pharmacology, Faculty of Medicine, King Abdulaziz UniversityJeddah, Saudi Arabia; Inflammatory Bowel Disease Research Group, King Abdulaziz UniversityJeddah, Saudi Arabia.
Jamil A Al-MughalesDepartment of Microbiology and Immunology, Faculty of Medicine, King Abdulaziz UniversityJeddah, Saudi Arabia; Inflammatory Bowel Disease Research Group, King Abdulaziz UniversityJeddah, Saudi Arabia.
Yagoub Y Bin-TalebDivision of Pediatric Gastroenterology / Department of Pediatrics, Faculty of Medicine, King Abdulaziz University Jeddah, Saudi Arabia.
Raed S BaeshenDiagnostic Immunology Laboratory, Faculty of Medicine, King Abdulaziz University Jeddah, Saudi Arabia.
King Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-33 (IL-33) is a cytokine that belongs to the interleukin-1 family and has been shown to be associated with mucosal inflammation. The aim of this study was to determine the serum level of IL-33 in children with ulcerative colitis (UC) and Crohn's disease (CD) and to correlate the level with the disease progression. In this cross sectional prospective study, we enrolled 50 children with IBD from KAUH, Jeddah, Saudi Arabia and 34 healthy control subjects between June 2012 and December 2012. Serum IL-33 was assessed by ELISA and CRP by immunonephelometric assay. Results from our study showed 32 CD and 18 UC patients included. The median age was 13.5 years for CD patients, 11.9 years for UC patients and 11.2 years for controls. Females constituted 53%, 66.7% and 59% of CD, UC and control subjects respectively. The median serum IL-33 in UC patients of 55.5 pg/mL was significantly higher than the median IL-33 level of 41 pg/mL in the healthy control (P=0.04) but no significant difference was found between the median IL-33 level in the sera of CD and the control group (P=0.7). A higher median IL-33 level was also found in active disease (P=0.03). In our cohort, the serum level of IL-33 was positively correlated with hs-CRP (r=0.48, P < 0.001). To conclude, our results support that serum IL-33 level is increased in children with UC as compared with control. Serum level is correlated with the disease activity; therefore it could be used as a potential biomarker for monitoring the severity of the disease in children with UC.

Indexed as

AdolescentAge FactorsBiological ProductsBiomarkersCase-Control StudiesChildColitis, UlcerativeC-Reactive ProteinCrohn DiseaseCross-Sectional StudiesDiagnosis, DifferentialEnzyme-Linked Immunosorbent AssayFemaleHumansInflammation MediatorsInterleukin-33Biological ProductsBiomarkersC-Reactive ProteinIL33 protein, humanInflammation MediatorsInterleukin-33childrenCrohn’s disease (CD)IL-33Saudi Arabiaulcerative colitis (UC)

Identifiers

PMID26884875
PMCPMC4730088
OpenAlexW2275280504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.